Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 24-07-2023 | Lung Cancer | short review

Lipid nanoparticles in the treatment of lung cancer—hype or hope?

Authors: Anna Mair, MD, Fabienne Nocera, MD, Univ.-Prof. Dr. Dominik Wolf, MD, PD Dr. Andreas Pircher, PhD, MD

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Summary

Lung cancer is still one of the most common cancer entities worldwide and the leading cause of cancer mortality. Despite significant advances in the diagnosis and therapy of lung cancer, many patients do not respond to existing therapies, indicating an urgent need for the development of novel treatment strategies. In recent years, nanotechnology has led to significant progress in modern medicine. Especially lipid nanoparticles (LNPs) evoked substantial interest, due to their broad application as coronavirus disease 2019 (COVID-19) vaccines. In the future of lung cancer treatment, lipid nanoparticles hold the potential to provide specific, safe, and well-tolerated treatments by incorporating multiple drugs and targeting agents and enabling their trafficking to tissues or cell types of interest. This review briefly summarizes the application of LNPs in lung cancer treatment as well as their future possibilities.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting? Front Oncol. 2018;8:267. https://doi.org/10.3389/fonc.2018.00267.CrossRefPubMedPubMedCentral

Tan Q, Saggar JK, Yu M, Wang M, Tannock IF. Mechanisms of drug resistance related to the microenvironment of solid tumors and possible strategies to inhibit them. Cancer J. 2015;21(4):254–62. https://doi.org/10.1097/PPO.0000000000000131.CrossRefPubMed

Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11. https://doi.org/10.1186/s40169-018-0185-6.CrossRefPubMedPubMedCentral

Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637–57. https://doi.org/10.2147/IJN.S23696.CrossRefPubMedPubMedCentral

Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79. https://doi.org/10.1016/j.ejpb.2015.03.018.CrossRefPubMed

Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater. 2023;8(4):282–300. https://doi.org/10.1038/s41578-022-00529-7.CrossRefPubMedPubMedCentral

Sheoran S, Arora S, Samsonraj R, Govindaiah P, Vuree S. Lipid-based nanoparticles for treatment of cancer. Heliyon. 2022;8(5):e9403. https://doi.org/10.1016/j.heliyon.2022.e09403.CrossRefPubMedPubMedCentral

Celgene Corporation. Abraxane® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) [albumin-bound]: US prescribing information [Internet]. 2014 [cited 09 May 2023]. Available from: http://www.fda.gov/.

10.

Socinski MA, Manikhas GM, Stroyakovsky DL, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(6):852–61. https://doi.org/10.1097/jto.0b013e3181d5e39e.CrossRefPubMed

11.

Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3(4):930–46. https://doi.org/10.20517/cdr.2020.68.CrossRefPubMedPubMedCentral

12.

Tan H, Hu J, Liu S. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol. 2019;47(1):268–77. https://doi.org/10.1080/21691401.2018.1552595.CrossRefPubMed

13.

Li Y, Lee RJ, Yu K, et al. Delivery of siRNA using lipid nanoparticles modified with cell penetrating peptide. ACS Appl Mater Interfaces. 2016;8(40):26613–21. https://doi.org/10.1021/acsami.6b09991.CrossRefPubMed

14.

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–94. https://doi.org/10.1038/s41578-021-00358-0.CrossRefPubMedPubMedCentral

15.

Zhang H, Leal J, Soto MR, Smyth HDC, Ghosh D. Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments. Pharmaceutics. 2020;12(11):1042. https://doi.org/10.3390/pharmaceutics12111042.CrossRefPubMedPubMedCentral

16.

Castañón E, Zamarin D, Carneiro BA, et al. Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14–19; Orlando, FL. Philadelphia (PA): AACR. Cancer Res. 2023;83(8_Suppl):Abstract nr CT4.CrossRef

17.

Tolcher A, Spira A, Nemunaitis J, et al. First-in-human dose-escalation study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with non-small cell lung, pancreatic, or colorectal cancer. In: Proceedings of the American Society of Clinical Oncology Annual Meeting 2023; Poster Session (Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology; Sub Track: New Targets and New Technologies (non-IO)). 2023 June 2–6; Chicago. p. Abstract nr 3084.

18.

Thomas A, Jain N, Nazaripour S, et al. Lipid nanoparticle library towards development next generation genomic medicines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14–19; Orlando, FL. Philadelphia (PA): AACR. Cancer Res. 2023;83(7_Suppl):Abstract nr 4066.CrossRef

19.

Prod’homme TE, Argueta S, Zhao H, et al. In vivo delivery of novel CD89 fusion receptor to myeloid cells by mRNA activates anti-tumor immunity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14–19; Orlando, FL. Philadelphia (PA): AACR. Cancer Res. 2023;83(8_Suppl):Abstract nr LB27.

20.

Data retrieved from US National Library of Medicine. http://clinicaltrials.gov/. Accessed 9 May 2023.

21.

Xu K, Dai L, Gao GF. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. Int Immunol. 2021;33(10):529–40. https://doi.org/10.1093/intimm/dxab061.CrossRefPubMed

22.

Huang T, Peng L, Han Y, et al. Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects. Front Immunol. 2022;13:922301. https://doi.org/10.3389/fimmu.2022.922301.CrossRefPubMedPubMedCentral

23.

Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265–80. https://doi.org/10.1038/s41576-021-00439-4.CrossRefPubMedPubMedCentral

24.

Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840–54. https://doi.org/10.1038/s41587-022-01294-2.CrossRefPubMed

25.

Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21(4):261–82. https://doi.org/10.1038/s41573-021-00387-y.CrossRefPubMedPubMedCentral

26.

Raimondo TM, Reed K, Shi D, Langer R, Anderson DG. Delivering the next generation of cancer immunotherapies with RNA. Cell. 2023;186(8):1535–40. https://doi.org/10.1016/j.cell.2023.02.031.CrossRefPubMed

27.

Zhang D, Wang G, Yu X, et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022;17(7):777–87. https://doi.org/10.1038/s41565-022-01122-3.CrossRefPubMedPubMedCentral

28.

Di J, Du Z, Wu K, et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm Res. 2022;39(1):105–14. https://doi.org/10.1007/s11095-022-03166-5.CrossRefPubMedPubMedCentral

29.

Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313–20. https://doi.org/10.1038/s41565-020-0669-6.CrossRefPubMedPubMedCentral

Title: Lipid nanoparticles in the treatment of lung cancer—hype or hope?
Authors: Anna Mair, MD
Fabienne Nocera, MD
Univ.-Prof. Dr. Dominik Wolf, MD
PD Dr. Andreas Pircher, PhD, MD
Publication date: 24-07-2023
Publisher: Springer Vienna
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Solid Tumor
Published in: memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00904-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2023

Late complications after oncological therapy

Head and neck cancer revisited

Nasopharyngeal carcinoma

Long-term survival and follow-up care after cancer in Austria

New developments in radiation oncology for head and neck cancers

Aggressive B cell lymphomas—highlights from ASH 2022

Keynote webinar | Spotlight on antibody–drug conjugates in cancer